Imiquimod Cream
NDC Package 72189-084-24
Package Information
Imiquimod cream is a medication used to treat certain types of growths on the skin. This formulation utilizes a cream delivery system. Marketed by Direct Rx, this product is identified by NDC 72189-084 and is authorized under FDA application ANDA078837.
Identification & Billing
- RxCUI: 310982 - imiquimod 5 % Topical Cream
- RxCUI: 310982 - imiquimod 50 MG/ML Topical Cream
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72189 - Direct Rx
- 72189-084 - Imiquimod
- 72189-084-24 - .25 g in 1 PACKET
- 72189-084 - Imiquimod
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72189-084-24 identifies a specific commercial package of .25 g in 1 packet of Imiquimod, a human prescription drug labeled by Direct Rx. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This cream is formulated for topical use and contains imiquimod as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Direct Rx on March 23, 2020. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain types of growths on the skin. These are precancerous growths (actinic keratoses), a certain type of skin cancer (superficial basal cell carcinoma), and warts on the outside of the genitals/anus. Treating these conditions can decrease complications from them. Imiquimod belongs to a group of drugs called immune response modifiers. It is believed to work by helping to activate your immune system to fight these abnormal skin growths. This product is not recommended for use on children under 12 years of age unless specifically directed by your doctor.
How is this Direct Rx product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72189008424. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.